推荐产品
product name
吉非替尼, ≥98% (HPLC)
品質等級
化驗
≥98% (HPLC)
形狀
powder
顏色
white to beige
溶解度
DMSO: 10 mg/mL, clear
儲存溫度
room temp
SMILES 字串
COC(C=C(N=CN=C1NC2=CC(Cl)=C(F)C=C2)C1=C3)=C3OCCCN4CCOCC4
InChI
1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
InChI 密鑰
XGALLCVXEZPNRQ-UHFFFAOYSA-N
基因資訊
human ... EGFR(1956)
正在寻找类似产品? 访问 产品对比指南
應用
吉非替尼已用于:
- 研究其在子宫内膜癌治疗中的有效应用
- 细胞增殖、细胞周期和细胞凋亡试验
- 细胞活力测定和集落形成试验
生化/生理作用
吉非替尼是一种选择性表皮生长因子受体酪氨酸激酶 (EGFR TK) 抑制剂。吉非替尼具有抗肿瘤活性,已被批准用于治疗非小细胞肺癌 (NSCLC)。
吉非替尼对 EGFR 酪氨酸激酶结构域中 ATP(三磷酸腺苷)结合站点的亲和力高于 ATP。因此,已知吉非替尼可抑制子宫内膜癌的进展。
吉非替尼对 EGFR 酪氨酸激酶结构域中 ATP(三磷酸腺苷)结合站点的亲和力高于 ATP。因此,已知吉非替尼可抑制子宫内膜癌的进展。
訊號詞
Danger
危險分類
Acute Tox. 4 Oral - Aquatic Chronic 1 - Carc. 2 - Eye Dam. 1 - Repr. 1B - Skin Irrit. 2 - STOT RE 2 Oral
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
其他客户在看
The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma.
Cancer Research, 78(11), 2839-2851 (2018)
The oncologist, 7 Suppl 4, 9-15 (2002-08-31)
Despite the advent of cisplatin-based combination chemotherapy for advanced non-small cell lung cancer (NSCLC), the prognosis for this patient population remains poor. Novel biologically targeted agents currently in development have the potential for greater efficacy against NSCLC, and possibly less
Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1.
Oncotarget, 8(70), 115360-115360 (2017)
Silencing of long non-coding RNA MIAT sensitizes lung cancer cells to gefitinib by epigenetically regulating miR-34a.
Frontiers in Pharmacology, 9, 82-82 (2018)
Current oncology (Toronto, Ont.), 22(3), e183-e215 (2015-06-20)
This systematic review addresses the use of epidermal growth factor receptor (egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients-unselected, selected, and molecularly selected-in three treatment settings: first line, second line, and maintenance. Ninety-six randomized controlled trials
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门